Head to Head Review: Nyxoah (NASDAQ:NYXH) versus Spectral AI (NASDAQ:MDAI)

Spectral AI (NASDAQ:MDAI) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Spectral AI and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Nyxoah	0	0	5	0	3.00

Spectral AI currently has a consensus price target of $4.50, suggesting a potential upside of 134.38%. Nyxoah has a consensus price target of $17.00, suggesting a potential upside of 105.94%. Given Spectral AI’s stronger consensus rating and higher possible upside, analysts plainly believe Spectral AI is more favorable than Nyxoah.

Profitability

This table compares Spectral AI and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-40.78%	N/A	-77.87%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Risk & Volatility

Spectral AI has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Valuation and Earnings

This table compares Spectral AI and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$27.26 million	1.31	-$20.85 million	($0.65)	-2.95
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.87)	-4.41

Spectral AI has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

67.1% of Spectral AI shares are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Spectral AI beats Nyxoah on 11 of the 14 factors compared between the two stocks.

About Spectral AI

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.